Cequa (ciclosporin 900 microgram/mL) is a newly-approved immunosuppressant indicated to increase tear production in affected patients where prior use of...
Read moreA new study has demonstrated that a particular biomarker can be used to select which age-related macular degeneration (AMD) patients...
Read moreAustralia’s ophthalmic community has welcomed the approval of Novartis’ latest therapy for neovascular age-related macular degeneration (nAMD). Advocates hope the...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited